Phase I Study of Flavone Acetic Acid (NSC 347512, LM975) in Patients with Pediatric Malignant Solid Tumors

C. Pratt,M. Relling,W. Meyer,E. Douglass,S. Kellie,L. Avery
DOI: https://doi.org/10.1097/00000421-199112000-00005
1991-12-01
American Journal of Clinical Oncology
Abstract:To evaluate the anticancer agent flavone acetic acid (FAA). we conducted a Phase I trial involving 17 pediatric patients with various malignant solid tumors. Dosages investigated included 5.120 and 6,144 mg/m2 given as 3-hour intravenous infusions: and 10.000. 12.500. 15.000. and 17.500 mg/m2 delivered in a 24-hour constant infusion with alkalinization. Grade 2 or worse toxicity was minimal, with 2 patients having nausea/vomiting, 2 having diarrhea. 1 becoming hypertensive, 1 becoming hypertensive, and 2 having myalgia. Three patients who received a 17.500 mg/m2 dose had no toxicity. Disease was stabilized for a brief period in 2 patients—1 with brain stem glioma and 1 with astrocytoma. The FAA pharmacokinetics varied with an average (SD) terminal half-life of 27.9 hr (18.7), clearance of 2.041/hr/m2 (0.37), and steadystate volume of 19.9 L/m2 (10.6). This study was discontinued because FAA caused no significant toxicity or therapeutic responses at doses 2.5 gm/m2 greater than had been tolerated by adults.
What problem does this paper attempt to address?